Octavio Espinoza - Aug 28, 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Financial Officer
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
Stock symbol
LGND
Transactions as of
Aug 28, 2024
Transactions value $
$50,086
Form type
4
Date filed
8/30/2024, 09:00 PM
Previous filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $11.8K +207 +0.88% $57.22 23.9K Aug 28, 2024 Direct
transaction LGND Common Stock Options Exercise $38.2K +546 +2.29% $70.04 24.4K Aug 28, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -207 -2.75% $0.00 7.31K Aug 28, 2024 Common Stock 207 $57.22 Direct F1
transaction LGND Incentive Stock Option (right to buy) Options Exercise $0 -546 -100% $0.00 0 Aug 28, 2024 Common Stock 546 $70.04 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter.
F2 As per the separation of OmniAb Inc. from the issuer, 402 stock options were vested and exercisable as of November 1, 2022, whereas 144 options vest in 3 substantially equal monthly installments beginning on December 1, 2022.